A Phase 3 interventional study of tamsulosin hydrochloride in Urological Manifestations, sponsored by Boehringer Ingelheim. Completed at 40 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An actual use study to assess how men who respond to advertisements about urinary symptoms use tamsulosin in a simulated Over the Counter (OTC) setting including following "stop use and ask a doctor if" and "ask a doctor before use" statements and if they take the medication according to the label instructions, also assess any reported adverse events during simulated OTC use.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tamsulosin hydrochloride
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the Drug Facts Label (DFL) within the first 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population is presented along with 95% exact two sided Clopper-Pearson confidence interval.
Time frame: 12 weeks
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL during the study (i.e., 24 weeks) and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.
Time frame: 24 weeks
Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.
Time frame: Week 12
Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.
Time frame: Week 24
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within the first 12 weeks of using the study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval
Time frame: 12 weeks
Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1
Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.
Time frame: 24 weeks
Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition
Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 who reported a symptom or condition is presented along with 95% exact two sided Clopper-Pearson confidence interval.
Time frame: 24 weeks
Percentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1
Percentage of men who sought advice of a physician within the first 12/24 weeks of the study out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval
Time frame: Week 12 and Week 24
Percentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1
Percentage of men who took two or more capsules per day within the first 12/24 weeks of using study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval
Time frame: Week 12 and Week 24
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 1737 | 364 |
| Completed | 1730 | 361 |
| Not completed | 7 | 3 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 964 | 153 |
| Completed | 754 | 127 |
| Not completed | 210 | 26 |
| Withdrew: Physician decision | 25 | 7 |
| Withdrew: Adverse event | 36 | 5 |
| Withdrew: Lost to follow-up | 76 | 7 |
| Withdrew: Withdrawal by subject | 60 | 3 |
| Withdrew: Investigator decision | 0 | 1 |
| Withdrew: Other than specified above | 13 | 3 |
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the Drug Facts Label (DFL) within the first 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population is presented along with 95% exact two sided Clopper-Pearson confidence interval.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1 | 0.2 (0.0 to 0.8) |
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL during the study (i.e., 24 weeks) and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1 | 0.2 (0.0 to 0.8) |
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks | 1.0 (0.1 to 3.4) |
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks | 0.9 (0.1 to 3.3) |
Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within the first 12 weeks of using the study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1 | 22.4 (19.8 to 25.2) |
Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1 | 20.3 (17.8 to 23.1) |
Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 who reported a symptom or condition is presented along with 95% exact two sided Clopper-Pearson confidence interval.
| Percentage of participants | Cohort 1 |
|---|---|
| Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition | 84.3 (78.9 to 88.8) |
Percentage of men who sought advice of a physician within the first 12/24 weeks of the study out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval
| Percentage of participants | Cohort 1 |
|---|---|
| Week 12 (N=924) | 43.1 (39.9 to 46.3) |
| Week 24 (N=924) | 56.4 (53.1 to 59.6) |
Percentage of men who took two or more capsules per day within the first 12/24 weeks of using study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval
| Percentage of participants | Cohort 1 |
|---|---|
| Week 12 (N=924) | 7.6 (6.3 to 10.0) |
| Week 24 (N=924) | 9.5 (8.1 to 12.1) |
Collected over From the first drug administration until 3 days after the treatment phase, up to 171 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | — | 54/927 (5.8%) | 61/927 (6.6%) |
| Cohort 2 | — | 12/150 (8%) | 25/150 (16.7%) |
| Cohort 1 and 2 | — | 66/1,077 (6.1%) | 86/1,077 (8%) |
| Event | Cohort 1 | Cohort 2 | Cohort 1 and 2 |
|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 1/927 | 1/150 | 2/1077 |
| Coronary artery occlusionCardiac disorders | 1/927 | 1/150 | 2/1077 |
| Myocardial infarctionCardiac disorders | 2/927 | 1/150 | 3/1077 |
| Chest painGeneral disorders | 2/927 | 1/150 | 3/1077 |
| HypersensitivityImmune system disorders | 0/927 | 1/150 | 1/1077 |
| CellulitisInfections and infestations | 0/927 | 1/150 | 1/1077 |
| PneumoniaInfections and infestations | 1/927 | 1/150 | 2/1077 |
| Respiratory tract infectionInfections and infestations | 0/927 | 1/150 | 1/1077 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/927 | 1/150 | 1/1077 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/927 | 1/150 | 1/1077 |
| Event | Cohort 1 | Cohort 2 | Cohort 1 and 2 |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 48/927 | 17/150 | 65/1077 |
| Back painMusculoskeletal and connective tissue disorders | 15/927 | 8/150 | 23/1077 |
Analysis Set for Cohort 1 and 2: This set included all men who were currently not using a prescription medicine for BPH (Cohort 1) or were currently using a prescription medicine for BPH (Cohort 2) and who answered the purchase question in Part 1. (Age is missing for 8 men)
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 61.8 ± 11.67 | 68.3 ± 9.10 | 63.0 ± 11.53 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 1731 | 362 | 2093 |
Ran from Sep 2015 to primary completion in Aug 2016, 10 months.
Results were first posted in Apr 2020, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin
Urological Manifestations